AI-Generated Image

Aurora Cannabis Inc. ACB has partnered with Vectura Fertin Pharma, Inc. to launch a CBD lozenge in the form of a dissolvable tablet that delivers the precise dose of cannabidiol (CBD). The new product is expected to enhance patient care by providing an alternative consumption method without psychoactive effects.



The partnership leverages Aurora&#8217;s extensive medical cannabis patient platform, said Aurora CEO Miguel Martin, who added that the company intends to broaden Canadian healthcare options with innovative products.



&#8220;Our partnership aligns with our commitment to meet Canada&#8217;s evolving healthcare needs,&#8221; Martin <a href="https://www.vecturafertinpharma.com/aurora-cannabis-and-vectura-fertin-pharma-inc-announce-commercial-collaboration/">stated</a> in a press release. 



<h3 class="wp-block-heading">NASDAQ Cannabis Titan With Global Reach</h3>



Aurora's international sales hit C$39.3 million ($28.9 million) in early 2024. This is a 31% increase year-over-year. Growth was aided by acquiring MedReleaf <a href="https://www.benzinga.com/topic/australia-cannabis">Australia</a>. Aurora now controls over 30% of <a href="https://www.benzinga.com/topic/canada-cannabis">Canada's medical marijuana </a>exports.



Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.



<h3 class="wp-block-heading">Profitability And Operational Efficiency in Cannabis </h3>



Aurora<a href="https://www.benzinga.com/quote/acb"> reported </a>increased adjusted cash gross margins rose 69% in June, up from 66% in March. However, operational expenses were 102% of adjusted cash gross profits. Still, Aurora&#8217;s net cash position rose to C$63 million. Positive operating cash flows reached C$8.4 million for the quarter.



<h3 class="wp-block-heading">Valuation And Market Position</h3>



Aurora Cannabis is valued at C$516 million with an enterprise value of C$543 million. It trades at 1.6 times its current sales, lower than competitors like Tilray TLRY and Canopy Growth CGC. A recent<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40512437/aurora-cannabis-dominates-30-of-canadas-medical-marijuana-exports-will-its-bold-int"> analysis</a> done by Pablo Zuanic highlighted Aurora&#8217;s solid financial and operational performance, maintaining an attractive valuation compared to its peers.



Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40325566/these-3-cannabis-companies-hold-cultivation-licenses-in-germany-a-1-8b-market-opportunity">These 3 Cannabis Companies Hold Cultivation Licenses In Germany: A ~$1.8B Market Opportunity?</a>

Cannabis

News

Health Care

Retail Sales

Markets

The cannabis company on Nasdaq has partnered with Vectura Fertin Pharma, to launch a dissolvable tablet that delivers a precise dose of CBD.

NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership - Aurora Cannabis (NASDAQ:ACB), Canopy Gwth (NASDAQ:CGC)

Nicolás Jose Rodriguez

Aurora Cannabis

Tilray Brands

Canopy Gwth

Canada Cannabis

Miguel Martin

Vectura Fertin Pharma

TLRY

NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership

Aurora Cannabis Inc

Canopy Growth Corp

Tilray Brands Inc

Application error: a client-side exception has occurred (see the browser console for more information).